Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P.

Checkpoint Capital L.P. trimmed its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 42.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,750 shares of the company’s stock after selling 45,241 shares during the period. Kymera Therapeutics accounts for about 1.2% of Checkpoint Capital L.P.’s investment portfolio, making the stock its 9th biggest holding. Checkpoint Capital L.P. owned approximately 0.09% of Kymera Therapeutics worth $3,495,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of KYMR. Bamco Inc. NY bought a new position in Kymera Therapeutics in the third quarter valued at approximately $396,000. Bank of America Corp DE raised its position in shares of Kymera Therapeutics by 38.0% during the 3rd quarter. Bank of America Corp DE now owns 186,254 shares of the company’s stock valued at $10,542,000 after acquiring an additional 51,315 shares during the last quarter. Braidwell LP bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $15,661,000. Alliancebernstein L.P. lifted its stake in shares of Kymera Therapeutics by 3.7% in the 3rd quarter. Alliancebernstein L.P. now owns 48,769 shares of the company’s stock valued at $2,760,000 after purchasing an additional 1,729 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Kymera Therapeutics by 23.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 24,058 shares of the company’s stock valued at $1,362,000 after purchasing an additional 4,525 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $123.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Piper Sandler increased their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. HC Wainwright raised their target price on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citigroup boosted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Insider Activity at Kymera Therapeutics

In related news, Director Bruce Booth sold 81,866 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the transaction, the director directly owned 675,341 shares in the company, valued at approximately $60,868,484.33. The trade was a 10.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the sale, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 196,561 shares of company stock valued at $17,097,428 over the last 90 days. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Stock Up 2.0%

KYMR opened at $79.03 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The company has a fifty day simple moving average of $79.21 and a 200 day simple moving average of $68.32. The stock has a market cap of $6.45 billion, a P/E ratio of -21.48 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. The business’s revenue was down 60.8% on a year-over-year basis. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.